• Aardvark Therapeutics will hold its 2026 annual stockholders meeting virtually on Aug. 14, 2026.
• Shareholders will vote to elect two Class I directors, including Jeffrey Chi and Victor Tong, for terms running to the 2029 annual meeting.
• The meeting will also seek approval to reprice certain outstanding stock options under the 2017 Plan, the 2025 Plan, and the 2025 Inducement Plan.
• A separate vote will cover ratification of BDO USA as independent auditor for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-288409), on June 29, 2026, and is solely responsible for the information contained therein.